For Tim Costello and approved people only

The Magnetics Roll-Up

Everyone is pouring billions into reshoring magnet PRODUCTION (MP Materials, Vulcan, USA Rare Earth, Niron), but almost no one is funding the magnetizing, orientation, characterization and design-software EQUIPMENT those plants run on — a layer that is today imported from Japan/China or bought used, and is fragmented across tiny, family-owned, undercapitalized shops. That equipment-and-services layer is unconsolidated, buyable at mid-single-digit EBITDA multiples, and re-rates to 12-20x+ once assembled into a scaled, recurring-revenue platform — the proven buy-and-build arbitrage behind Judges Scientific, Transcat and the Swedish compounders. Tim Costello — who ran Global Operations at Applied Materials (the literal namesake), launched GM's EV1, is Shingo Hall of Fame on lean, and already built-and-exited a roll-up of a fragmented family-owned industry (BHI → Zonda → CoStar, $800M) — is the operator a founder sells to and a PE partner backs, with Polymagnet's programmable-magnet IP as the crown jewel that cuts rare-earth intensity and de-commoditizes the whole platform.

🔒 Proprietary & Confidential — the candidate names and framing on this page are for Tim and approved people only. Do not forward.
12candidates mapped
6Priority A
11on the floor at MMM
11comps studied

The thesis

Why this, why Tim, why now

THE WHITE SPACE (externally validated). US magnet-production reshoring is now a multi-billion-dollar, federally-backed build-out — MP Materials (Pentagon its largest shareholder, $400M preferred + $150M loan + 10-yr NdPr price floor; Apple $500M supply deal), Vulcan Elements (>$1B Nov 2025 incl. a reported ~$620M DoW loan + CHIPS + Commerce equity), USA Rare Earth (Stillwater OK sintered-NdFeB line), and Niron (rare-earth-free). But the magnetizing / orientation / characterization / QC / design-software EQUIPMENT those plants depend on is imported (Japan's ULVAC is re-shoring its OWN furnace production; USA Rare Earth bootstrapped on USED NdFeB equipment) and takes years to assemble (Adamas Intelligence). No US/Western-owned, consolidated equipment-and-service platform exists. That is the picks-and-shovels gap Tim's roll-up fills — reported fact, not assertion.

THE INDUSTRY IS GENUINELY FRAGMENTED. The MMM 2026 exhibit floor is a live roster of the thesis: of ~13 exhibitors, roughly 9 are tiny family- or founder-owned equipment/instrument shops — Hirst (UK, ~60 yrs, private), GMW (CA, employee-owned, ~20 staff), Group3/G3 (NZ, owner-operated, ~7 staff), Hinds (OR, Hinds family since 1971), NanoMagnetics (founder Prof. Oral). Tim's own slide-7 targets (Oersted, 360 Magnetics, Magnetic Instrumentation, Bunting; Hirst, Eckel, MAGSYS) map onto real, small, independent firms. The pure pulse-magnetizer market is only a few hundred $M — so the roll-up case rests on margin, recurring service/calibration/consumables and strategic position, NOT raw TAM.

THE ECONOMIC ENGINE — multiple arbitrage plus a recurring-revenue re-rate. Small, family-owned instrument/equipment businesses transact at roughly 4-7x EBITDA (Judges Scientific pays ~5x EBIT; LMM midpoint ~5.5x), while a scaled, diversified instrument platform is valued at ~12-20x+ (Judges ~11.6x EV/EBITDA, Transcat ~18.9x, Veralto ~16.9x, Spectris taken private by KKR at 19.5x EBITDA). A Bain-referenced finding holds that reducing the average entry multiple contributes ~8 percentage points/yr of equity-value CAGR — i.e. the arbitrage, not operational magic, is the dominant return driver. The second lever is converting a hardware cost-of-goods business into software + ISO-17025 calibration + data/traceability + design-IP royalties; across 400+ deals, hardware traded ~1.4x revenue vs software ~3.0x. Treat all multiples as a diligence FRAMEWORK to re-source (PitchBook/CapIQ), never as committed numbers.

WHY NOW IS ACUTE. China controls ~70% of rare-earth mining, ~90% of processing and ~93% of magnet manufacturing (CSIS) and in 2025 weaponized it: April 2025 controls on 7 medium/heavy REEs, an October 2025 expansion reaching foreign-made magnets with >=0.1% Chinese-origin REE AND magnet-making technology/equipment, and from Dec 1 2025 denial of licenses to foreign military-affiliated buyers. EO 14241, DPA Title III, the EU Critical Raw Materials Act (10/40/25/65 benchmarks) and a live US Section 232 probe on permanent magnets all push subsidized Western magnet + equipment capacity. A Western-owned magnetizing + QC capability reads as a national-security asset — which supports premium multiples and government/PE co-investment.

CONSOLIDATION HAS ALREADY STARTED — the window is closing. PE is already running this exact play one adjacency over: Arcline's DwyerOmega precision-measurement platform (Dwyer 2021 + Omega carved from Spectris 2022 + a string of bolt-ons) pulled magnetics IN via Lake Shore Cryotronics (family-owned since 1968, acquired June 2026). Carlson Private Capital bought Quantum Design (Oct 2024), which then took Oxford Instruments' NanoScience unit for GBP60M. KLA holds MicroSense + Capres (2019). The measurement side is being professionalized by sponsors NOW — but no one owns the magnetizing + design-software + domestic-service core. Correct the record: DwyerOmega's owner is Arcline (PE, >$30B AUM), NOT Novanta.

WHY TIM, NOT A FINANCIAL SPONSOR. Family founders in this segment sell to a steward/operator who understands the technology and keeps the business alive — Tim's exact profile (Applied Materials Global Ops; GM EV1; Shingo Hall of Fame lean; BHI 1,300-builder roll-up exited through Zonda to CoStar at $800M — the exit chain is independently verified; the AMAT/GM/Shingo bio is self-reported on the deck and should be backed with a press/LinkedIn citation before external use). The value creation here is operational (build US service/calibration, centralize engineering, bolt on software), which is Tim's toolkit — and Polymagnet's programmable-magnet IP cuts rare-earth intensity, selling the exact China-exposure reduction every reshoring customer is buying.

STRATEGY: build a US nucleus first. Fix the deck's own 'weak US support' gap with a domestic magnetizing cluster — Oersted (OR), Magnetic Instrumentation (IN), 360 Magnetics + QT (CA), GMW (CA), Group3's new Cerritos arm — assembled without crossing borders, then extend into EU magnetizing (MAGSYS, Hirst) and the global measurement standard-bearers (Group3, GMW) for metrology credibility. Hold Judges-style entry discipline (hard 4-7x cap, ROTIC/IRR hurdle >15%): Judges' own post-mortems show IRRs collapse above ~7x EBIT without organic growth, and sellers raise prices once a roll-up is known. The first diligence workstream is the quantified value-creation bridge the roll-up deck itself admits is missing (entry multiples, target EBITDA, synergy stack, exit multiple).

The tailwind

The wind at the back of this deal

Why the magnetics-equipment layer is strategically scarce right now.

China's near-monopoly is the structural scarcity driver — and it is being weaponized, which makes a Western-owned magnetizing + QC capability effectively a national-security asset (supports premium multiples and government/PE co-investment).

2025 export controls reached not just rare-earth magnets but magnet-making TECHNOLOGY and equipment, and (from Dec 1 2025) deny licenses to foreign military-affiliated buyers — directly raising the value of Western-owned equipment capability. (Expiry timeline unsettled: Nov 10 2026 vs a reported Jan 10 2027 extension — unconfirmed in official notices; cite MOFCOM directly.)

Unprecedented government + strategic capital is behind Western magnet PRODUCTION — the customer base for a magnetizing/calibration platform. (Exact figures vary by source; verify vs SEC filings.)

The US 'magnet gap' is the near-term account list: ~48,000 MT consumed vs ~300 MT domestic output (directional, trade-press), pulling >38,000 MT/yr of announced US NdFeB capacity on-line — every new plant needs magnetizing + ISO-17025 calibration/measurement gear.

The equipment layer is the overlooked, un-funded bottleneck — reshorers depend on Japanese/Chinese equipment makers or used gear, and standing up capacity 'requires years.' This is the white space, now third-party-validated.

Policy pull on two continents is locked in: EO 14241 + DPA Title III (US), the EU Critical Raw Materials Act (10% extraction / 40% processing / 25% recycling / max 65% single-country by 2030, rare earths named strategic), and a live US Section 232 probe covering permanent magnets (outcome not yet public).

Market sizing (cite as RANGES — vary ~2x by scope): permanent-magnet materials ~$28-55B in 2026 (~6-8% CAGR, NdFeB ~64% share); magnetic test & measurement ~$3-4B in 2025 to ~$6-8B by 2032-34; pure magnetizing equipment only ~$0.37-0.41B (so sell on margin/services/strategic position, not raw TAM).

The playbook

How instrument roll-ups get built and funded

The comps a PE partner already believes in. Tim's thesis is this playbook, aimed at magnetics.

Judges Scientific plc (LSE: JDG) — UK scientific-instrument buy-and-build

THE LESSON IN ONE LINE: The discipline is the whole business — the multiple you pay is the moat, and the one deal that breaks the rule can undo a decade of compounding. Five transferable takeaways for a magnetics-equipment roll-up: 1) PRICE DISCIPLINE IS NON-NEGOTIABLE, AND IT IS THE STRATEGY. Judges' edge was never clever operating magic — it was buying niche #1/#2 manufacturers at 3-6x EBIT and refusing to go higher. The spread between a low private entry multiple and the higher multiple the platform earns is the compounding engine. For fragmented magnetics-equipment firms (Halbach-array makers, magnetizers/fixturing, measurement/metrology, custom assemblies), set a hard multiple cap up front and publish it to your PE partners. 2) THE CAUTIONARY TALE IS REAL AND RECENT. The one time Judges broke its own ~6x cap — Geotek, ~£80m at ~7x in 2022, its "transformational" deal — group after-tax ROTIC collapsed 17%->9%, the stock fell ~two-thirds from its 2024 peak, and analysts re-rated it "a less capable acquirer." Tim's takeaway: one oversized, over-multiple, cycle-peak acquisition can erase years of disciplined gains. Be willing to WALK from the marquee deal. 3) DECENTRALIZE — BUY IT, DON'T BLEND IT. Keep founders, brands, engineering teams and customer relationships intact; impose only financial control (cash, capital allocation, debt paydown) from a deliberately tiny centre (~£4m/yr at a ~£145m-revenue group). Magnetics firms are deep-domain, relationship-driven engineering shops — integration destroys exactly what you paid for. This also makes the platform a friendly home for retiring founders, which wins proprietary (non-auctioned) deals. 4) STRUCTURE PRICE RISK OUT WITH EARN-OUTS AND DEBT ~50/50. Pay vendors for profit actually delivered, fund ~half with cheap debt sized to the target's own cash flow, recycle free cash into the next deal. Avoid paying full freight for peak-cycle earnings — critical because scientific/industrial capex (and magnetics demand tied to EV, motors, medical, defense R&D) is lumpy and cyclical. 5) GO SLOW AND DIVERSIFY THE NICHES. ~1 deal/year, small tickets, many independent niches. Judges' recent pain was partly customer/contract concentration (lumpy "coring expedition" revenue). A magnetics roll-up should spread across sub-niches and end-markets so no single cyclical customer or contract swings the group. NET: Pitch the PE room on the multiple-arbitrage + autonomy flywheel Judges proved over ~20 years and ~86x — but lead with the discipline guardrails, because Judges itself just demonstrated, in public and in the share price, what happens when you relax them.

LONG-RUN RETURN (the headline): - ShareScope (2023-11-17): 95p IPO (Jan 2003) to ~£82 (Nov 2023) ≈ ~86x; from a 60p 2009 low to £82 = a "136-bagger." (ShareScope's figures; multi-decade CAGR ≈ ~24% from 2003 IPO — analyst arithmetic, not an audited figure.) - AJ Bell (2024-02-15): 16.2% annual total return over the prior 10 years — ~£1,000 (2014) -> ~£4,500 incl. dividends. [dated] - Shares peaked >£100 in early 2024, then fell ~two-thirds (MoneyWeek). Price ~3,550p on 2026-10-14, valuing EV at ~£285m at ~9x normalised profit (ii). [These are dated spot figures.] ACQUISITION MULTIPLES & FINANCING: - Entry price cap: "up to 6x operating profit" / 3-6x EBIT (some cite 3-7x). Implied min pre-tax ROTIC ~16.7%. [ShareScope] - ~50% debt-financed; can borrow ~3x target EBITDA; balance from cash + earn-outs. [analyst summaries] - Geotek (2022, ~£80m) bought at ~7x profit — ABOVE the 6x cap; the exception. [ShareScope] RETURN ON CAPITAL: - ROTIC historically ~15-30% (to ~46% some years). [ShareScope] - Group after-tax ROTIC fell 17% (2022) -> 9% (2025) after Geotek. [ii 2026] - Operating-level return reported >40% in 2025 (different, pre-capital-base measure). [ii 2026] SCALE / RECENT RESULTS (RNS + secondary summaries): - FY2024: revenue £133.6m (-1.9%), PBT £13.0m (-3.0%), dividend 104.5p (+10%). [AJ Bell / RNS] - H1 2025: revenue £70.2m (+15%), adj PBT £12.6m (+17%). [RNS 2025-09-18] - FY2025 (unaudited prelim, 2026-03-31): revenue £145.8m (+9.1%), adj operating profit £28.0m (+0.4%), PBT £8.9m (-32%); organic order book 15.7 wks vs 18.7. [RNS] - H1 2026 trading update: revenue -21% YoY, adj PBT -75%; order intake -11%. [ii; RNS] CAVEAT: Figures are from RNS announcements and reputable secondary/analyst sources, not re-derived from audited accounts; some (order-book weeks, 2024 comparatives) were restated between releases. No private/ownership data fabricated.

1 2 3 4 5 6 7 8 9

The Instrument-Roll-Up Majors: AMETEK / Danaher / Roper / Halma / Spectris — compounding playbook for Tim Costello's magnetics thesis

The companies that earn premium multiples (and attract KKR-type capital) do NOT win on vision — they win on a repeatable, teachable OPERATING SYSTEM applied to every acquisition. Before the roll-up story sells to PE, build and name your "Magnetics Business System": the specific playbook (sourcing, lean, pricing, cross-sell, new-product cadence) you drop onto each acquired magnet/equipment shop to lift its margin the way DBS lifted Danaher +600bps. The system is what de-risks the thesis for a sponsor. Second: magnetics EQUIPMENT alone is project/capital-heavy and will earn a low, cyclical multiple. The compounders escaped that by deliberately engineering a recurring, high-margin layer — Roper (76% software), Danaher (consumables). Polymagnet's programmable-magnet IP is your software-equivalent, high-margin, royalty/licensing asset; pair it with service, calibration, measurement, and consumable/material streams so the platform is re-rated as "instrumentation + recurring IP," not "equipment." That mix shift is the difference between an 8x business and a 20x one. Third: your setup is exactly what this capital prizes. AMETEK buys "leading positions in niche markets"; Halma buys "global market niches." Fragmented magnetics, full of niche leaders, IS the ideal substrate — frame the thesis in their language. And the exit evidence is live and specific: KKR just paid ~£4.7bn for Spectris in a contested 2025 auction against Advent. Private capital is actively competing for precision-instrumentation platforms right now — that is your comp and your exit-multiple proof point for the war-room. Fourth, the checklist to walk into PE conversations with: (1) the named operating system, documented; (2) a deep proprietary bolt-on pipeline at single-digit-to-low-teens multiples (show the names, not a TAM slide); (3) a recurring-revenue / IP-royalty layer with pricing power; (4) organic growth, not just acquired — the market pays a premium for the organic half (Roper's 6% organic inside 14% total); (5) niche leadership + clean financials + an integration bench. Lead with the system and the pipeline. The "Applied Materials of Magnetics" line lands only when it sits on top of those five proofs. CAVEAT to keep the war-room honest: every company figure above is sourced to filings/IR/press; the EV/EBITDA multiple RANGES are illustrative estimates, not live quotes (web-search budget was exhausted this session) — label them as such and refresh with current data before any number goes in front of a sponsor.

SOURCED (primary filings / company IR / cited press): - Danaher FY2024: sales $23,875M (flat vs $23,890M FY23); gross margin 55.7%→59.5% (2019→2024); adjusted operating margin 22.3%→28.6%, i.e. +600bps+; Abcam acquired Dec 2023 for ~$5.7B; Masimo agreed at $180/share (announced, into Diagnostics segment). [Danaher 2024 Annual Report, SEC] - Roper FY2024: revenue +14% to $7.0B (6% organic + 8% acquisitions); FCF +16% to $2.3B; ~$3.6B deployed on acquisitions (Procare ~$1.86B, Transact Campus ~$1.6B); software recurring/reoccurring base ~$4.6B; software ~10%→~76% of revenue over 15 yrs. [Roper FY2024 10-K & Annual Report, SEC] - AMETEK FY2024: record net sales $6,941.2M (+5.2% vs $6,597.0M); record EBITDA $2,151.6M (vs $2,014.7M) = ~31% EBITDA margin; >$150M operational efficiencies in 2024; Paragon Medical ~$1.9B. [AMETEK FY2024 10-K & Annual Report, SEC] - Halma FY2025/26 (year ended 31 Mar 2026): revenue £2,582M (+15%); adjusted EBIT £594M (+22%) = ~23% margin; ROTIC 16.2% (+120bps); 23rd consecutive year of adjusted profit growth. [halma.com/investors] - Spectris: KKR won a 2025 auction over Advent; KKR offer valued Spectris at ~£4.7bn incl. debt (~$6.46bn) vs Advent's earlier ~£3.73bn; precision-instrumentation maker, founded 1915, ~7,600 employees; UK court approved 2 Dec 2025. [en.wikipedia.org/wiki/Spectris + cited press] ILLUSTRATIVE / ESTIMATE (NOT sourced live — label as such to Tim; multiples move daily and I could not pull current quotes this session): public instrument-compounders have historically traded in roughly the ~18–25x EV/EBITDA / high-20s–30x P/E range, while the niche bolt-ons they buy typically transact at ~8–14x EBITDA. The gap between those two ranges is the "multiple arbitrage." The Spectris £4.7bn take-private is a hard, sourced data point on what a scaled precision-instrumentation platform fetches; the exact implied EV/EBITDA is an estimate pending Spectris's last reported EBITDA. Treat all multiple ranges as directional, not quotes.

1 2 3 4 5 6 7

Instrument & Test-and-Measurement Valuation Benchmarks — the buy-and-build multiple-arbitrage playbook

The prize isn't magnetics innovation — it's the multiple. Magnetics equipment is structurally the same as the scientific-instrument and T&M niches Judges, Halma, AMETEK and Danaher have already consolidated: hundreds of sub-scale, founder-owned, high-gross-margin, IP-rich B2B makers with no natural exit. Value is created by (1) buying them at mid-single-digit EBIT/EBITDA multiples with disciplined, decentralized M&A, (2) assembling them into one branded, diversified platform that institutions and PE value at 20x+ EBITDA, and (3) letting re-rating + modest leverage + organic growth compound. That is a ~5x-in / 20x+-out spread, and it is a de-risked playbook — not a theory — because four separate companies have run it to scale in adjacent instrument verticals, and KKR just paid £4.7bn to take one (Spectris) private. The discipline that makes it work, and the exact lines to carry into a PE conversation: never overpay at entry (cap ~7x EBIT — the deal engine dies if you chase); keep leverage at or below ~3x the target's EBITDA; keep acquired founders' teams running their own businesses; buy roughly one good company a year, not one bad empire; and position Correlated Magnetics / Polymagnet as the branded technology anchor the platform compounds around. The pitch to a sponsor: a proven consolidation model applied to a vertical (magnetics) that nobody has rolled up yet — all of the arbitrage, none of the "will the playbook work" risk. One caveat to state plainly to Tim and to PE: the cleanest entry-multiple evidence (4-6x EBIT) comes from investor analyses of Judges rather than audited disclosure, and the public comps are an aggregator's figures — anchor the model on Judges' audited annual report and on a banker's fairness-opinion comp set before any number goes into an LOI or IC memo.

ENTRY (small private niche instrument/T&M maker) — what consolidators actually pay: - Judges Scientific paid multiples: average ~4-6x EBIT; full range 3x (financial-crisis low) to ~7x (Geotek, 2022, its largest at £80m); ~7x is the stated ceiling. [per three independent investor write-ups — ltir.substack, compoundandfire.substack, riccardosorelli.substack — mutually consistent; secondary, confirm vs. Judges' annual report] - Typical Judges deal size ~£6-12m. [riccardosorelli] - Leverage at entry: up to ~3x target EBITDA; balance in cash + earn-out. [all three] - Derived entry EV/revenue: first deal FTT (2005) had £3m sales / £0.75m EBIT, bought at 5x EBIT = ~£3.75m → ~1.25x revenue. [DERIVED from ltir figures — illustrative of the entry end] - General lower-middle-market rule of thumb: sub-$5-10M EBITDA businesses commonly transact ~4-8x EBITDA. [ILLUSTRATIVE industry rule of thumb — not a single-source figure] SCALED PLATFORMS (exit end) — current public trading multiples, source stockanalysis.com (data aggregator), all as of 31 Oct 2026: - Halma plc: EV/EBITDA 21.2x | EV/revenue 5.3x | P/E 35.1 | EV £13.8bn | rev £2.58bn - Mettler-Toledo (MTD): EV/EBITDA 27.9x | EV/revenue 8.6x | P/E 37.7 | EV $35.6bn | rev $4.13bn - Keysight (KEYS): EV/EBITDA 30.9x | EV/revenue 8.0x | P/E 42.2 | EV $52.5bn | rev $6.58bn - Danaher (DHR): EV/EBITDA 22.5x | EV/revenue 7.2x | P/E 38.0 | EV $185bn | rev $25.6bn - AMETEK (AME): EV/EBITDA 22.8x | EV/revenue 7.3x | P/E 35.3 | EV $57bn | rev $7.86bn - Judges Scientific (AIM, mid-cap serial acquirer): EV/EBITDA 13.1x | EV/revenue 2.1x | fwd P/E 17 | EV £275m | rev £131m (trailing net loss, so trailing P/E n/a) SECTOR AGGREGATES — Aswath Damodaran / NYU Stern, EV/EBITDA by industry, Jan 2026 (public-company universe): - Electronics (General): 20.0x (positive-EBITDA firms) / 25.9x (all); 114 firms - Semiconductor Equipment: 24.7x; 31 firms - Electrical Equipment: 24.6x / 35.0x; 112 firms - Machinery: 16.2x; 105 firms - Total US market: 19.7x; 5,994 firms REAL RECENT PE TAKE-PRIVATE OF A SCALED T&M PLATFORM (exit precedent): - Spectris plc: KKR agreed July 2025 at £4.7bn incl. debt, beating Advent's £3.73bn; completed Dec 2025. [Wikipedia, citing Reuters — secondary] Spectris FY2024 revenue £1,299m, operating profit £134.3m. [stockanalysis.com] Implied EV/revenue ~3.6x [DERIVED]. Two global PE firms competed to own a scaled T&M platform — direct evidence of sponsor appetite for exactly this exit. THE ARBITRAGE MATH (the headline): - Buy at ~5x EBIT (~1.2-1.3x revenue) privately → the same EBITDA is marked at ~13x inside a mid-cap serial acquirer, and 20-31x inside a large branded platform; revenue at 2x → 5-9x. - So ~£1 of EBITDA acquired for ~£5 is valued at ~£13-£30 once inside a scaled platform: a ~2.5x-6x markup from multiple re-rating alone, before leverage, organic growth or cross-sell. - Compounding proof (Judges): started 2002 with £2m capital; 25 businesses; 2024 revenue £133m; profit CAGR ~26% since inception; share price ~20%/yr long-run. [ltir / riccardosorelli — secondary]

1 2 3 4 5 6 7 8 9 10 11 12

Magnetics / Lab-Instrument Roll-Up Comps — Who Already Consolidates, and the Playbook (for Tim Costello's war room)

THE LESSON (specific, for the war room): 1. The thesis is validated — but the crown jewel is already taken. "The Applied Materials of Magnetics" is a real, precedented play (KLA, Nova, AMETEK, Halma, Judges all prove instrument roll-ups compound). BUT the obvious pure-play anchor, Lake Shore Cryotronics, is already inside Arcline's DwyerOmega. So Tim is not first to the best measurement asset. Two consequences: (a) move on the remaining fragmented independents before Arcline/AMETEK/KLA sweep them, and (b) don't position as a Lake Shore competitor you must out-buy — position as the consolidator of everything Lake Shore's owner ISN'T prioritizing (magnetizers, field generation, Helmholtz/coils, materials, test systems, calibration/service), i.e., own the full magnetics STACK, not just metrology. 2. Know which rival you're facing on each target, because it changes the price. On semiconductor/magnetic-recording-metrology targets you'll lose to KLA/Nova/AMETEK (they pay revenue-synergy prices). On broad niche-instrument targets you compete with Halma/Judges/AMETEK on discipline. On platform-scale deals you face Arcline and KKR/Spectris money. Tim's edge cannot be price — it has to be operator credibility (CMR/Polymagnet domain depth), speed, and being the trusted "good home" for a retiring founder. That's the same edge Halma and Judges actually win on. 3. Multiple arbitrage is the whole game, and so is discipline. The return comes from buying sub-scale founder businesses at mid-single-digit EBITDA and re-rating them inside a platform worth mid-teens+. But Judges Scientific's market cap fell ~41% — proof that roll-ups de-rate hard when they overpay or growth stalls. The binding constraint is entry multiple discipline, not deal volume. Underwrite every bolt-on to stand alone. 4. MMM 2026 Honolulu this week is the pipeline, not just a booth. The exhibitor floor is literally the fragmented target universe — sensor, gaussmeter, magnetizer, Helmholtz, materials, and test-system makers, many founder-owned and near succession. Use the show to build the target map (founders, ages, succession risk, rough size) and to pre-position Polymagnet/CMR as the friendly consolidator, so PE conversations have a named, sequenced pipeline rather than a thesis. Spectris→KKR (Dec 2025) and the Advent/KKR bidding war show PE appetite for instrument platforms is hot right now — the window to raise and anchor is open.

SOURCED (cite URL). Figures are as reported on the cited pages; where a date/value could not be confirmed in-session it is labeled. OMEGA / DWYEROMEGA / ARCLINE (en.wikipedia.org/wiki/Omega_Engineering): - Omega founded 1962; 2010 revenue $168M. - Spectris bought Omega 2011 for $475M; took £115M impairment Mar 2017. - Arcline bought Omega from Spectris, announced 19 Apr 2022, for $525M; merged into Dwyer Group → renamed DwyerOmega. LAKE SHORE CRYOTRONICS (lakeshore.com): confirmed "now part of DwyerOmega" (Arcline-backed), per Lake Shore's own site referencing press release "arcline-backed-dwyeromega-acquires-lake-shore-cryotronics." EXACT ACQUISITION DATE AND DEAL VALUE NOT CONFIRMED IN-SESSION (reported ~2023; do not quote a date without re-verifying). KLA (en.wikipedia.org/wiki/KLA_Corporation): FY2025 (ended 6/30/2025) revenue $12.2B, net income $4.06B, total assets $16.1B; Orbotech acquired ~$3.4B (announced 2018, closed Feb 2019). - CAPRES (micro four-point-probe metrology): capres.com issues a 301 → kla.com/about (confirms KLA ownership via live redirect; CAPRES acquisition DATE reported 2019 but NOT confirmed in-session). - MicroSense (magnetic/wafer metrology): microsense.net issues a 302 → kla.com/products/chip-manufacturing/metrology (confirms KLA ownership via live redirect; date NOT confirmed in-session). NOVA LTD — NVMI (en.wikipedia.org/wiki/Nova_Measuring_Instruments): 2024 revenue $672.4M (+30% YoY); 2025 revenue ~$881M (infobox). Acquisitions: HyperNex 2006; Revera 2 Apr 2015 for $46.5M; ancosys Feb 2022 ~$100M all-cash; Sentronics Metrology early 2025 ~$60M. Listed Nasdaq + TASE. NOVANTA — NOVT (stockanalysis.com/stocks/NOVT/; investors.novanta.com): FY2025 revenue $980.6M (+3.3% from $949.25M in 2024); market cap $5.51B (as of Oct 30–31, 2026). Medical + advanced-industrial precision tech; brands incl. Celera Motion, ATI, Jadak, WOM, Ingenia. Nasdaq: NOVT. AMETEK — AME (en.wikipedia.org/wiki/Ametek): 2024 revenue $6.94B, net income $1.37B (2023 $6.59B; 2022 $6.1B). ~95 acquisitions listed since 1998 (incl. Zygo optical metrology, Edax, Quizix). Two groups: Electronic Instruments Group + Electromechanical Group. NYSE: AME. SPECTRIS (en.wikipedia.org/wiki/Spectris): taken private by KKR — £4.7B (~$6.46B incl. debt), court-approved 2 Dec 2025. Advent had bid £3.73B (~$5.06B) June 2025; KKR agreed July 2025. Owned/owns Omega (sold 2022), Malvern Panalytical, HBK, Particle Measuring Systems, Red Lion, Servomex. HALMA — HLMA (stockanalysis.com/quote/lon/HLMA/; en.wikipedia.org/wiki/Halma_plc): FY2026 revenue £2.58B (+14.87%), earnings £372.3M; market cap £13.02B (Oct 30, 2026); ~9,000 employees; founded 1894; three segments (Safety / Environmental & Analysis / Healthcare), ~34+ named subsidiaries. JUDGES SCIENTIFIC — JDG (stockanalysis.com/quote/lon/JDG/): FY2025 revenue £145.8M (+9.13%); earnings £5.5M (down ~47%); market cap ~£226M (DOWN ~41.5% — notable de-rating). Two segments (Materials Sciences + Vacuum); founded 2002; 791 employees. AIM: JDG. (Its famed low-multiple buy-and-build discipline is widely reported but a specific target EV/EBIT multiple was NOT confirmable in-session — judges.uk currently redirects to an unrelated site.) METHOD NOTE: WebSearch budget for the session was exhausted before this task ran; all figures above come from direct WebFetch of the cited pages (Wikipedia, company sites, stockanalysis.com) and two live domain-redirect confirmations. Treat every item marked "NOT confirmed in-session" as needing a second source before it goes in front of a PE counterparty.

1 2 3 4 5 6 7 8 9 10 11 12 13

Judges Scientific (LSE: JDG)

The single closest proven analog and the entry-discipline anchor: a listed buy-and-build of niche scientific-instrument makers. Copy its template line-for-line — hard 3-7x EBIT entry cap, ~50% debt per deal, leverage capped ~3x EBITDA, cash swept to repay acquisition debt then re-levered, decentralized hold-forever, asset-light. Its own post-mortems show IRRs collapse above ~7x EBIT without organic growth — so entry discipline IS the credibility test.

~25 niche instrument businesses acquired since 2005 at an average ~5x EBIT (range 3-7x; In Practise pegs ~6x avg vs Halma ~7.5x). 19-yr revenue CAGR ~19%, EBIT CAGR ~23%; ROTIC averaged ~16% since 2007. Trades ~11.6x EV/EBITDA. CAUTION: cyclical — H1-2026 profit fell 66% and ROTIC dipped below 10% in a soft patch.

Spectris plc / KKR (take-private)

The best 'what a scaled platform is worth' anchor — a diversified, recurring-revenue instrument group attracts both PE and strategics at a large premium, and a bidding war (Advent vs KKR) proves the demand.

KKR's July 2025 recommended cash offer of GBP40.00/share (~GBP4.1bn equity, ~GBP4.7-4.8bn EV) = 19.5x FY2024 Adjusted EBITDA / 23.0x Adjusted EBIT. Final recommended price rose to ~GBP41.75/share (no published EV/EBITDA for the final price). For contrast, listed peers Oxford Instruments ~10x, Renishaw ~13x.

Transcat (NASDAQ: TRNS)

The cleanest fragmented-market roll-up POSITIONING comp — 'acquirer of choice in a fragmented market' of tiny calibration/instrument-service firms, winning on fast repeatable integration. Almost exactly Tim's structural picture, with the added lever of centralized US sales/service.

Targets mostly $0.5M-$10M revenue; ~$1.4bn addressable, highly fragmented calibration market with a long tail of $0.5M-$5M providers. Re-rated to ~2.8x revenue / ~18.9x EV/EBITDA.

Arcline / DwyerOmega — Lake Shore Cryotronics

THE live proof the thesis is real AND already being executed in magnetics — and the competitive clock. A PE platform (Arcline, >$30B AUM) rolling up precision measurement pulled a family-owned (Swartz family since 1968) magnetics/cryogenic-measurement maker IN. Template: operator-led platform + PE capital + bolt-ons. CORRECT THE RECORD: owner is Arcline, NOT Novanta.

Acquired June 10 2026; terms undisclosed (Houlihan Lokey advised). DwyerOmega bolt-ons include Dwyer (2021), Omega (carved from Spectris 2022 at ~$525M), Process Sensing Technologies, Burns Engineering (Jan 2026), SOR Controls Group, Lake Shore (June 2026).

Carlson Private Capital — Quantum Design Int'l

A SECOND PE-backed consolidator already buying in cryogenic/magnetics measurement, now running its own bolt-on strategy — reinforcing that the attractive measurement assets have competing buyers and a closing window. Also a usable valuation anchor for thin-margin magnetics hardware.

QD acquired Oct 11 2024 (Houlihan Lokey advised; Yukon Partners junior capital). QD then agreed to buy Oxford Instruments' NanoScience unit for GBP60M (~1.0x revenue on ~GBP59M sales / ~GBP1M adj. operating profit) — frame Polymagnet's software/IP/recurring layer as what lifts a platform above a ~1x-revenue hardware multiple.

Swedish compounders — Lifco & Addtech

The hardest evidence the buy-low/trade-high spread PERSISTS across decades and is the dominant return driver — back it with the Bain-referenced finding that entry-multiple reduction is worth ~8%/yr of equity CAGR.

Lifco has acquired at ~7.5x EV/EBITA on average while the group trades >20x EV/EBITA; Addtech's older deals ~5x EV/EBIT, now ~7x, while valued up toward ~30x EV/EBIT. (Substack/advisory-sourced — re-check vs primary reports before quoting as hard fact.)

The large-cap operating systems — Danaher, Roper, AMETEK, Halma

The 'operating system' narrative PE expects, and the credible basis for 'the Applied Materials of Magnetics': buy niche #1s, improve them with a repeatable system (DBS/kaizen), sweep cash, buy again, periodically spin out. AMETEK/KLA are also plausible eventual strategic exit buyers for a built-up platform.

Roper targets mid-teens cash-flow compounding (doubling ~every 5 yrs). AMETEK: acquisitions ~73% of $8.6bn deployed since 2010; deal-level entry multiples not disclosed. Halma: ~7.5x EBIT bolt-ons, run at ~1x net-debt/EBITDA, ~GBP515m across 6 deals in 2026.

  • ILLUSTRATIVE FRAMEWORK ONLY — not a sourced magnetics transaction. Every input must be replaced with diligenced figures (PitchBook/CapIQ/broker) before use. It shows the SHAPE of the return, grounded in the sourced entry/exit ranges above.
  • ENTRY (fragmented, family-owned): acquire ~6-8 magnetics-equipment makers at a blended ~5.5x EBITDA — Judges/LMM discipline (Judges ~5x EBIT; LMM midpoint ~5.5x; hard cap 4-7x).
  • BUILD A ~$25M-EBITDA PLATFORM: ~$140M invested, financed ~50% debt (Judges template), leverage capped ~3x EBITDA, opco cash swept to repay acquisition debt, then re-lever for the next deal.
  • RE-RATE AT EXIT: value the scaled, diversified group at even ~12x EBITDA (BELOW Transcat ~19x, Veralto ~17x, Spectris' 19.5x take-private, ~ Judges' ~11.6x public) => ~$300M EV — roughly 2x the capital invested from multiple re-rating ALONE, before any organic growth or debt paydown.
  • UPSIDE LEVER: at a 16-18x strategic/public exit the equity multiple is materially higher; converting hardware revenue to software + ISO-17025 calibration + data/royalties re-rates revenue from ~1.4x toward ~3.0x (400+-deal medians).
  • THE VALUE-CREATION BRIDGE to underwrite = acquired EBITDA growth + organic growth + multiple re-rating + deleveraging. HONESTY GATE: the re-rating piece depends on reaching real scale (~$50M+ EBITDA) and a strategic/public exit — overclaiming the exit multiple on sub-scale EBITDA is the classic roll-up red flag. Do NOT put specific purchase multiples on Tim's named targets in the deck; none are public — label any as illustrative pending diligence.

The multiple math above is an illustrative framework drawn from public comps, not a forecast. Real numbers come from the deal model.

The board

The candidates

Ranked by fit and approachability. Tap any company for the full dossier, decision-makers, and a first-contact note drafted in your voice.

More roll-up ideas →
15 more candidate companies (the keystone: Magnet-Physik, which owns both the magnetizing stack and the Permagraph measurement standard), 7 adjacent segments, 9 ways to structure the play, and 9 second-platform roll-ups. Plus the consolidation clock.
Open the expansion

This week

The MMM 2026 play

Concrete moves on the floor in Honolulu that advance the roll-up — partner and customer framing, never "I want to buy you."

Outreach

Templates and first contacts

Ready to adapt. Warm, operator-to-operator, no deck attached.

Hirst (Booth 12) — the delicate one, neighbor framing, NEVER 'acquisition' on the floor
Jim — we're your next-door neighbor at Booth 11. We write multipole patterns into magnets with capacitor-discharge pulses, and you've built pulse magnetisers and pulsed-field magnetometry for decades. I'm genuinely curious: could a PFM08 tell us anything useful about a magnet carrying a few hundred maxels? Happy to do a demo swap — I'll show you PolyDesk at 11 if you'll walk me through the PFM at 12. And I'll be at your GR-05 FORC poster Friday.
Measurement booths (G3 B13, GMW B2, Lake Shore B10, Spin Sensing B18) — one honest buyer-style discovery question
Quick question from someone who makes an unusual magnet: how would you check a programmed / multipole magnet, part by part, at line speed? And two follow-ups — who runs your North American sales and service today, and do you co-develop or OEM? (Priority order: Spin Sensing Factory first — their CE-04 paper reads a magnetization pattern back with TMR + deep learning, the most complementary work on the floor.)
Bunting (not exhibiting) — peer, not target
Robert — fellow magnet people. You've built a real global platform through Master Magnets and Magnet Applications; we've built programmable-magnet IP and a design-software stack. Worth comparing notes on where the industry is heading and whether there's a way our capabilities complement yours. (Internal note: Bunting is itself a serial acquirer post the June 2025 ownership transition — treat as a partner/merger-of-equals conversation, price accordingly, never a soft target.)
US magnetizing nucleus (Magnetic Instrumentation, Oersted, 360/QT) — technical-first, succession-aware
We design multipole magnet patterns and are building out US magnetizing, characterization and ISO-17025 calibration capability. Your magnetizers / fluxmeters / accredited lab are exactly the kind of capability our customers need domestically. Could we find 20 minutes to talk about co-development or supply — and, where it fits, a deeper partnership? (Internal: Magnetic Instrumentation = clean, professionally managed, accredited lab — lead here. Oersted = verify Oregon SOS status FIRST, site is dead, possible cheap asset pickup. QT/Quadrant founder Ron Zichterman, ~30 yrs = succession lever.)
Lab credibility — El-Ghazaly / Gachon / Ames (two-way technical, not a pitch)
Dr. El-Ghazaly — your work on reconfigurable magnetics and micron-scale Halbach patterns is the closest thing at MMM to what we do with programmed maxels. How do you pattern and measure a Halbach field at that scale? Would love 10 minutes and to show you our approach at Booth 11. (Also: Gachon's Won-Ho/Kyu-Seob Kim — the only post-assembly-magnetization/yoke-design group here; and Ames/CMI's Ikenna Nlebedim — the DOE rare-earth-reduction hub, directly on our material-reduction thesis.)
PE / family-office memo framing (NO named targets)
The thesis in one line: $2B+ is funding US magnet PRODUCTION, but the magnetizing/orientation/characterization/software EQUIPMENT those plants run on is imported or bought used, fragmented across tiny family-owned shops, and buyable at ~4-7x EBITDA — re-rating to 12-20x+ as a scaled, recurring-revenue platform (Judges, Transcat, Spectris, the Swedish compounders). PE is already running this one adjacency over (Arcline/DwyerOmega just pulled magnetics in via Lake Shore; Carlson owns Quantum Design) — but no one owns the magnetizing + design-software + US-service core. An operator who ran Applied Materials' global ops and already exited a fragmented-industry roll-up, with differentiated programmable-magnet IP that cuts rare-earth intensity, is the one to assemble it. First workstream is the quantified value-creation bridge; all multiples here are an illustrative framework to re-source in diligence.

Candor

Risks, and how we answer them

Confidentiality landmine THIS WEEK: the roll-up deck names Hirst as a target and was one-click downloadable off ceotim.com, while Hirst exhibits one booth from Tim.
Gate both decks behind request-access and cut a slide-7-free send copy BEFORE exhibits open; repoint booth QR to polymagnet.com; brief all booth staff that acquisition/target language never leaves the NDA room; have one honest line ready if Hirst has already seen it. (Content and link edits are low-risk; auth-rule changes need sign-off.)
Competing, better-capitalized consolidators are already moving — Arcline/DwyerOmega (>$30B AUM) now owns a magnetics beachhead (Lake Shore); Carlson owns Quantum Design. A pure buy-and-consolidate play gets outbid.
Speed + a differentiated operator/IP story founders prefer over a financial buyer. Lead with the magnetizing spine (Oersted, Magnetic Instrumentation, MAGSYS, Hirst, 360) — the cleaner, less-contested nucleus these PE platforms have NOT targeted.
Entry-multiple drift: once a roll-up is known, sellers raise prices and the arbitrage compresses; Judges' own deals show IRRs collapse above ~7x EBIT without organic growth.
State a hard entry cap (3-7x EBIT) and a ROTIC/IRR hurdle (>15%) in the deck; underwrite a real organic-growth/integration lever (US service, centralized engineering, software), not just 'own more magnetizers.'
The pure magnetizing-equipment TAM is only a few hundred $M — too small to carry a pure financial roll-up on market-size alone.
Sell on margin, recurring service/calibration/consumables and strategic position, riding the $28-55B magnet-materials market and the government-funded reshoring build-out. Cite market figures as sourced RANGES (they vary ~2x by methodology).
Feedstock dependence: reshoring magnet makers still lean on Chinese-licensed feedstock; a US-China thaw could soften the urgency.
The equipment/software/service layer is feedstock-AGNOSTIC and benefits from ferrite/alt-chemistry substitution — it wins regardless of who wins the materials race. And multi-year DoD offtakes/price floors plus >$1B of committed federal magnet capital are already sunk; the Dec 1 2025 military-buyer denial is structural.
Targets are sub-scale and founder-dependent; integration risk across US + Europe.
That is the acquisition opportunity (undercapitalized sellers, retiring founders) — and Tim has integrated a 1,300-member fragmented industry before. Apply a lean/Shingo operating system + a centralized equipment-engineering and 24/7 service backbone.
The quantified deal model (entry multiples, target EBITDA, synergy stack, exit multiple) is NOT yet built — the deck concedes this.
Make it the first PE diligence workstream, not a hidden flaw. It is literally the page-one question a sponsor asks; present the current multiples as a framework to re-source via PitchBook/CapIQ/broker data.
Unverified load-bearing facts could undercut credibility with investors.
Before external use: back Tim's AMAT/GM-EV1/Shingo bio with a press/LinkedIn citation (the BHI->Zonda->CoStar $800M exit IS independently verified); reconcile the patent count (deck '150+' vs public '90+') against the current USPTO assignee record; confirm 'RE MAGSYS' = MAGSYS Magnet Systeme GmbH and which 'Eckel' is meant; verify Oersted's Oregon entity status; confirm Spectris/KKR and Oxford NanoScience/QD closings; and cite MOFCOM Announcement 18/61 directly for export-control specifics.

Sources

Where this comes from

Every load-bearing claim traces to a public source. The dossiers link their own.